Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics (RNTX) reports that the RENEW Phase 2 clinical trial is subject to a clinical hold, creating uncertainty about timing and the studies or actions needed to resolve the hold. The company warns that delays could strain its cash resources and affect its ability to fund the trial and operations through completion. It also notes the risk that early-stage results may not be replicated later, potential difficulties enrolling patients, and challenges integrating Qureight's deep-learning platform into the trial. The filing points readers to the company’s 2024 Form 10-K for additional risk factors and reiterates standard forward-looking statement disclaimers.
Rein Therapeutics, Inc. (RNTX) entered a Pre-Paid Advance Agreement with YA II PN, Ltd. (Yorkville) allowing up to $6.0 million of prepaid advances over 12 months, each purchased at 95% of face value and due 12 months after issuance. Interest on outstanding advances accrues at 8% annually, rising to 18% upon certain defaults. An initial $1.0 million advance was purchased on the effective date for net proceeds of $0.95 million. The company issued 479,036 shares of common stock (average price ~$1.06 per share) to Yorkville, which were applied against $500,000 of the initial advance. The placement was done in a private transaction relying on Section 4(a)(2) of the Securities Act with no underwriter.
Rein Therapeutics, Inc. (RNTX) is registering shares in connection with a standby equity purchase agreement and related prepaid advance facility with Yorkville/YA II PN, Ltd. The company is developing peptide and proenzyme candidates LTI-03 and LTI-01 for fibrosis-related lung diseases; LTI-03 is the lead program with Phase 1b data and a planned 24-week RENEW trial, with initial data expected in 2026. LTI-01 completed Phase 2a and Phase 1b work but its development has been temporarily delayed and may remain paused pending funding. Under the Pre-Paid Advance Agreement, Rein may request up to $6.0 million in prepaid advances (purchased at a 5% discount) and has received an initial $1.0 million advance (net $950,000). Under the Standby Equity Purchase Agreement, the company could receive up to $15.0 million in aggregate gross proceeds if it sells Advance Shares to the selling stockholder; outstanding and potential share counts are disclosed.
On 29 Jul 2025 Rein Therapeutics (RNTX) entered two financing arrangements with YA II PN, Ltd. 1) Pre-Paid Advance Agreement (PPA): the company can draw up to $6.0 m over 12 months; Yorkville purchases each advance at 95% of face value (initial draw $1.0 m yielded $0.95 m). Interest accrues at 8% (18% upon default). Yorkville may force repayment in shares at the lower of 115% of prior-day VWAP or 95% of the lowest VWAP in the prior 7 trading days, but not below a $0.28 floor. Floor-price, registration-effectiveness or exchange-cap breaches trigger monthly cash amortization of up to 25% of the original advance.
2) Standby Equity Purchase Agreement (SEPA): provides an equity line of up to $15.0 m over 36 months. Each advance is priced at 96% of the lowest VWAP during the three days after an advance notice, subject to volume and minimum-price limits. Rein paid a $300 k commitment fee via 213,099 shares and $25 k expenses.
The aggregate shares issuable under both facilities are capped at 19.9% of current outstanding stock, and Yorkville’s ownership is limited to 4.99%. PPA shares will be issued off the company’s shelf registration; SEPA shares require an effective resale registration statement. The facilities give Rein up to ~$21 m in gross liquidity with flexible timing, but at the cost of discounted pricing, possible dilution and potential downward pressure on the share price.
Rein Therapeutics (Nasdaq: RNTX) filed a Rule 424(b)(5) prospectus supplement that amends its May 22 2025 at-the-market (ATM) shelf with H.C. Wainwright.
The filing reduces the remaining issuance capacity under the Form S-3 from $15.77 million to $8.07 million. The cut aligns with General Instruction I.B.6, which limits sales to one-third of the company’s $42.3 million public float (calculated on July 24 2025) during any 12-month period while the float remains below $75 million.
To date the company has raised only $35,460 (16,127 shares) through the ATM. Following the adjustment, up to approximately $8.03 million of common stock can still be issued from time to time. Additional supplements will be required if a larger float later permits greater issuance capacity.
RNTX shares last closed at $1.41 on July 28 2025. Investors should evaluate the dilution risk associated with future ATM sales versus the financing flexibility this mechanism provides.
Form 4 filing: Rein Therapeutics (RNTX) disclosed that director Manuel Aivado was granted a stock option for 17,500 common shares on 23-Jul-2025 at an exercise price of $1.55 per share, expiring 22-Jul-2035.
The option vests 100 % on the earlier of 23-Jul-2026 or the 2026 annual meeting, subject to continued board service. No open-market purchases or sales of common stock were reported, and Aivado’s post-transaction derivative holdings total 17,500 options, all held directly.
This is a routine equity-based compensation grant that does not immediately alter the public float or cash position. If exercised, the award would introduce only modest dilution, typical for small-cap governance practices, while further aligning the director’s interests with shareholders.
Rein Therapeutics (RNTX) filed a Form 4 disclosing a routine equity grant to independent director Alan A. Musso. On 07/23/2025 Musso received 17,500 non-qualified stock options exercisable at $1.55 per share, equal to the grant-date market price. The award vests 100 % on the earlier of 07/23/2026 or the company’s 2026 annual meeting, conditional on continued board service. Following the transaction Musso beneficially owns 17,500 derivative securities and no additional common shares were reported. Ownership is held directly; no indirect holdings were disclosed.
No sale of shares, cashless exercise, or change in overall insider ownership occurred, so immediate dilution is de-minimis. The filing is primarily administrative, aligning director incentives with shareholders.
FAQ
What is the current stock price of Rein Therapeutics (RNTX)?
What is the market cap of Rein Therapeutics (RNTX)?
